Some analysts have a lowest price target on Puma Biotechnology, Inc. (NASDAQ:PBYI) of $26, which would mean a -33.79% gain in value. The closing share price quoted for March 14, 2019 was $39.27. The -6.5% drop might have been tempting for an investor to sell at this point but in fact that would prove a short-sighted mistake, as sell-side analysts think there is almost 78.25% more gain yet to come for shareholders. Analysts seemed to set $70 as highest price target on its way to greater gains. The stock enjoyed an overall uptrend of 92.97% from the beginning of 2019. The average 12-month price target they expect from the stock is $42. This mean price target represents 6.95% upside over its previous closing price. The median price target they presented was $34 for the next 12-months, which suggests a -13.42% upside from current levels.
A fresh roundup today notes that PBYI stock has lost around -46.79% of its value in the past 12 months, suggesting more investors have expressed concern about about in that time period. If we turn to the Street in general, the negaitives still outweigh the positives as we can see that Puma Biotechnology, Inc. (PBYI), have a sell (3) analyst consensus rating. In the current time, the stock has 2 buy and 5 hold ratings. The stock registered its 52-week high of $76.45 on March 16 and its 52-week low of $17.6 on November 02. Currently, the shares are trading $10.72 above its YTD moving average of $28.55.
Moving on, Puma Biotechnology, Inc. (PBYI) last reported its December 2019 earnings. For brief highlights, it performed weak in that quarter, with earnings down -53% year-over-year at $-0.8. The company surprised analysts by 4 who were expecting $-0.77 per share. Overall, its quarterly revenues jumped by 229% to reach $71.1 million, while it had reported $21.6 million in the same period a year ago. To see what investors should really expect from its March 2019 financial results consensus analyst estimates are calling for current quarter earnings per share of $-0.69, down from $-0.65 in the same quarter a year ago. However, earnings-per-share are expected to see growth of 77.9% in next year. From there, the company believes it can achieve a long-term annual earnings growth rate of 0 %. At the other end of the income statement, we have seen revenue of $251 million over the trailing 12 months.
To help you decide whether it’s worth the wait (and the money), Puma Biotechnology, Inc. (NASDAQ:PBYI) is currently trading at 0X the company’s trailing-12-month earnings per share, which represents a discount compared to the sector’s 32.54X and comes in below its industry’s 69.36X. The most popular method for valuing a stock is to study the historic Price-to-Earnings (P/E) ratio using reported earnings for the past 12 months. The EPS number for this stock in the most recent four quarters of earnings stood at $-3. P/E ratio is so popular because it’s simple, it’s effective, and, tautologically, because everyone uses it.
The 14-day Absolute ATR (Average True Range) on Thursday, March 14 of 2019 shows that the price on average moves $2.21. The average daily volatility is 5.69% over the past week. Low volatility is good for the stock and it means we have calm and confident investors. If you check recent Puma Biotechnology, Inc. (PBYI) volume, you will see that it has changed to 1.09 million shares versus the average daily volume of 1.17 million shares.
When you look at the daily chart for PBYI, you will observe the stock held -16.8% losses in the 6-month period and maintains 123.12% distance from its most recent low. The past 5-day performance for the share stays positive at 2.88% but up 20.04% from its three-week moving average. Comparing to 50-day SMA, Puma Biotechnology, Inc. shares price is now up 39.39%. It also closed 2.81% higher from its 200-day SMA. This is often seen as the last line of defense for long term trends to find support at, else be considered broken and/or in a bear market. The daily chart of the stock more clearly reveals the slide in prices as it closed Thursday with a 1-month performance at 45.61%.
This post was originally published on *this site*